Sector: healthtesting
Conviction from: S&PCitrini
52-week range: 146.19379.63
Charles River Laboratories provides preclinical and clinical drug-development services, research models, and manufacturing-support services to pharmaceutical and biotech companies.
4 tracked filer(s) hold this · 2 opened, 1 added, 1 trimmed in 30-SEP-2026
Aggregate 13FScore 57 — mean of 4 scored holder(s) · buyers (new/add) avg 53. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Bridgewater | 55 | New buy | 70,553 | $20,813,841 | 0.1% |
| Paul Tudor Jones / Tudor | 61 | New buy | 44,921 | $13,252,144 | 0.0% |
| Ancora | 42 | Added +4% | 58 | $17,111 | 0.0% |
| Bill Nygren / Oakmark (Harris Associates) | 71 | Trimmed -37% | 1,410,332 | $416,062,043 | 0.5% |
Beyond 13F — activists, insiders, politicians & research
2 disclosed trade(s) by 1 filer(s).
| Report | Date | Stance |
|---|
| #135 — State of the Themes: The End of the Trade (As We Know It) | 2026-11-04 | LONG |
| #134 — Citrini Therapeutics: We Wanted to Use Claude to Create a New Drug | 2026-10-20 | LONG |
| #97 — Rough Seas Make Strong Sailors: Navigating the Healthcare Policy Tsunami | 2025-05-28 | WATCH |
| #92 — Market Memo: Talk to Me, Goose | 2025-04-13 | LONG |